The Era of Oral Weight-Loss Drugs: Who Has More Staying Power — Novo Nordisk or Eli Lilly?
Who’s winning the oral weight-loss drug race?
The GLP-1 weight-loss market is shifting from injectables to oral pills — and it’s still Novo vs. Lilly at the top.
Which giant has stronger long-term momentum? Let’s break it down clearly.
The weight-loss drug race is moving from the injectable first half to the oral second half.
Late last year, the first oral GLP-1 weight-loss drug was approved, and analysts project the market will near $100 billion by 2030.
At the table are the same two giants: Denmark’s Novo Nordisk (NVO) and U.S. star Eli Lilly (LLY).
In the injectable era, Lilly overtook the market with superior efficacy from tirzepatide (Mounjaro/Zepbound) and aggressive production expansion, capturing 60% of the U.S. market.
Now the battlefield has shifted to oral drugs. Can Novo Nordisk regain control with its first-mover advantage?
Will Lilly’s newly approved Foundayo repeat its comeback story?
$Novo-Nordisk A/S(NVO)$ : First to Market, Converting Existing Demand
Novo Nordisk’s confidence comes from its first-mover advantage.
Semaglutide launched as Ozempic back in 2017, and its oral version Wegovy was approved late last year as the world’s first oral GLP-1 weight-loss drug.
Its strength lies in user conversion.
The inconvenience of injectables has discouraged many potential patients, and oral pills have unlocked this demand.
A Truveta study shows more than 36% of oral Wegovy users are new to GLP-1s — meaning oral drugs are expanding the market, not just diverting injectable users.
As oral production ramps up, pent-up demand is turning into real revenue.
$Eli Lilly(LLY)$ : Winning with “Take With Food” Convenience & Efficacy Reputation
Lilly’s counter weapon is Foundayo, with convenience as its core selling point.
Current oral semaglutide has a clear drawback: it must be taken on an empty stomach, with no food or drink for at least 30 minutes after dosing.
This is inconvenient for people with busy, irregular lifestyles.
But clinical data for Foundayo shows it can be taken with food and drinks.
This small difference could become a major compliance differentiator for long-term use.
In addition, head-to-head studies in injectables already built Lilly’s brand as more effective.
Even without direct oral comparisons, the perception that tirzepatide beats semaglutide for weight loss is deeply rooted in doctors’ and patients’ decisions.
Entering the oral market with this reputation, Lilly naturally carries higher expectations.
Valuation & Finance: Who Is Paying for the Future?
Financial numbers clearly show the gap.
Last year alone, Lilly’s Mounjaro and Zepbound generated over $36 billion in revenue.
Novo Nordisk has similar scale, but its growth rate in the U.S. market has fallen noticeably behind.
Capital market pricing amplifies this gap:
-
Novo Nordisk is at a recent valuation low, offering some safety for value investors.
-
Lilly is at an all-time high, with a much higher P/E ratio — the market has fully priced in expectations that “Lilly will keep leading the oral market.”
Conclusion: Margin of Error Determines Long-Term Moment
Overall, Lilly has stronger staying power over the next three years.
Novo Nordisk’s growth depends heavily on two conditions:
its oral drug defends leadership, and injectables don’t decline.
If Foundayo uses its convenience to take share in the oral market, as Lilly did in injectables, Novo faces pressure on both earnings and valuation.
By contrast, Lilly’s tirzepatide injectables are already a stable cash cow, and oral Foundayo is upside optionality.
Even if the new drug underperforms, its 60% U.S. market share remains a solid base.
If its convenience advantage pays off, its growth ceiling rises even higher.
As analyst Adria Cimino put it:
Lilly at current levels is unlikely to be a “10-bagger.”
But for long-term portfolios, choosing the player with higher margin for error and stronger market dominance is usually the safer choice.
In this oral drug tug-of-war, Lilly is already in a more comfortable position.
For SG users only, Welcome to open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with unlimited trading on SG, HK, and US stocks, as well as ETFs.
🎉Cash Boost Account Now Supports 35,000+ Stocks & ETFs – Greater Flexibility Now
Find out more here.
Complete your first Cash Boost Account trade with a trade amount of ≥ SGD1000* to get SGD 688 stock vouchers*! The trade can be executed using any payment type available under the Cash Boost Account: Cash, CPF, SRS, or CDP.
Other helpful links:
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
- flixzy·04-12 21:04Novo's lead might hold, but Lilly's got the muscle. Tough call this one! [吃瓜]LikeReport